Key facts
- This page summarizes Tomas Kiselak's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2025, 16:46.
Tomas Kiselak - 01 Jul 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)
- Form type
- 4
- Accepted by SEC
- 02 Jul 2025, 16:46:45 UTC
- Previous filing
- 28 Jun 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Jennifer Tousignant, Attorney-in-fact
Source evidence
4 source fields
Reporting owner
1 detail
Key filing fact
Tomas Kiselak filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 02 Jul 2025.
Change
- Previous filing in this sequence was filed on 28 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001830177
Primary reporting owner
Kiselak Tomas
- Relationship
- Director
- Address
- C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
- Signature
- /s/ Jennifer Tousignant, Attorney-in-fact
- Signature date
- 02 Jul 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRDN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +21,000
- Change %
- Price
- $0.000000
- Shares after
- 21,000
- Date
- 01 Jul 2025
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 21,000
- Exercise price
- $14.47
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Footnote F2
Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.